Salta alla navigazione principale
Salta alla ricerca
Salta al contenuto principale
Università del Piemonte Orientale Home
Italiano
English
Cerca contenuto all’indirizzo Università del Piemonte Orientale
Home
Profili
Unità di ricerca
Apparecchiatura
Progetti
Risultato della ricerca
N- and k-ras oncogenes in plasma cell dyscrasias
Paolo Corradini
,
Marco Ladetto
, Giorgio Inghirami
, Mario Boccadoro
, Alessandro Pileri
Risultato della ricerca
:
Contributo su rivista
›
Articolo in rivista
›
peer review
Panoramica
Fingerprint
Fingerprint
Entra nei temi di ricerca di 'N- and k-ras oncogenes in plasma cell dyscrasias'. Insieme formano una fingerprint unica.
Ordina per
Peso
Alfabetico
Keyphrases
RAS Oncogene
100%
K-ras
100%
N-Ras
100%
Plasma Cell Dyscrasia
100%
Molecular Lesions
50%
KRAS mutation
50%
RAS Gene
50%
Myeloma
25%
Multiple Myeloma
25%
Monoclonal Gammopathy of Undetermined Significance
25%
Prognostic Factors
25%
Gene mutation
25%
Tumor Progression
25%
Purine
25%
Pyrimidine
25%
Extramedullary Plasmacytoma
25%
Codon
25%
Randomly Distributed
25%
Codon 12
25%
Tumor Initiation
25%
Heterogeneous Patterns
25%
Oncogene mutation
25%
Advanced Stage Disease
25%
Plasma Cell Leukemia
25%
KRAS Oncogene
25%
Medicine and Dentistry
Oncogene Ras
100%
Plasma Cell Dyscrasia
100%
Oncogene K Ras
100%
Codon
66%
Prevalence
33%
Multiple Myeloma
33%
Monoclonal Gammopathy of Undetermined Significance
33%
Tumor Progression
33%
Purine
33%
Gene Mutation
33%
Plasmacytoma
33%
Myeloma
33%
Ras Signaling
33%
Tumor Initiation
33%
Oncogene N Ras
33%
Plasma Cell Leukemia
33%
Diseases
33%
Pyrimidine
33%
Pharmacology, Toxicology and Pharmaceutical Science
Plasma Cell Dyscrasia
100%
Neoplasm
50%
Prevalence
50%
Monoclonal Immunoglobulinemia
50%
Multiple Myeloma
50%
Tumor Growth
50%
Myeloma
50%
Purine
50%
Pyrimidine
50%
Plasmacytoma
50%
Plasma Cell Leukemia
50%
Diseases
50%
Biochemistry, Genetics and Molecular Biology
Oncogene Ras
100%
Oncogene K Ras
100%
Immunoglobulin Producing Cell
100%
Codon
66%
Molecular Lesion
66%
Gene Mutation
33%
Prevalence
33%
Tumor Progression
33%
Tumor Initiation
33%
Oncogene N Ras
33%